Mer­ck kick-starts PhI­II cho­les­terol tri­als for its oral PC­SK9; Bax­ter re­calls 13,000+ vials of chemother­a­py

Mer­ck re­vealed Fri­day it start­ed up its first late-stage clin­i­cal pro­gram for an oral PC­SK9 in­hibitor for cho­les­terol.

The pro­gram is cur­rent­ly en­rolling par­tic­i­pants in two reg­is­tra­tional stud­ies for MK-0616, which aims to low­er LDL cho­les­terol. An out­comes study is al­so set to start this year, with plans to en­roll a com­bined 17,000 pa­tients be­tween all three tri­als.

The reg­is­tra­tional tri­als are ex­pect­ed to wrap up in 2025, and the out­comes study in 2029.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER